Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute · 2012
ClinicalTrials.gov · Datasets · License: Public Domain · 2012
Open Source ↗
breast-cancerovarian-cancer
ovarian cancer, breast cancer, recurrent, high grade, serous, triple negative, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 896906
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.